| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/02/2003 | EP1268421A2 Phenyl-substituted indoles as histamine h3-receptor antagonists |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268418A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 01/02/2003 | EP1268412A1 Sulphonamido-substituted bridged bicycloalkyl derivatives |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268404A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 01/02/2003 | EP1268396A1 Diphenyl ether compounds useful in therapy |
| 01/02/2003 | EP1268096A1 Extrusion die |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267912A2 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 01/02/2003 | EP1267911A1 A method of treatment |
| 01/02/2003 | EP1267909A1 Methods of blocking tissue destruction by autoreactive t cells |
| 01/02/2003 | EP1267906A1 Lactams as inhibitors of a-beta protein production |
| 01/02/2003 | EP1267896A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 01/02/2003 | EP1267892A2 Use of cdp-choline for the treatment of alcohol withdrawal syndrome |
| 01/02/2003 | EP1267882A2 Apoptosis inhibitor with prostaglandin structure |
| 01/02/2003 | EP1267878A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 01/02/2003 | EP1267869A1 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance |
| 01/02/2003 | EP1267867A1 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| 01/02/2003 | EP1267862A2 Methods and compositions for improving sleep |
| 01/02/2003 | EP1267853A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 01/02/2003 | EP1267849A2 Restricting reinstatement of drug use |
| 01/02/2003 | EP1267832A1 New self emulsifying drug delivery system |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1267760A2 Medical procedure |
| 01/02/2003 | EP1115716B1 2-phenylpyran-4-one derivatives |
| 01/02/2003 | EP1019374B1 Polymorphs of donepezil hydrochloride and process for production |
| 01/02/2003 | EP0980383B1 Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens |
| 01/02/2003 | EP0980382B1 Estrogenic 19-norandrost-17-one derivatives with an aromatic b-ring |
| 01/02/2003 | EP0751939B9 Naphthylamides as central nervous system agents |
| 01/02/2003 | EP0625988B1 Allosteric modulators of the nmda receptor |
| 01/02/2003 | CA2414726A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/01/2003 | CN1388132A Cell death inducing protein and its coding sequence and use |
| 01/01/2003 | CN1388131A Serial medicine carriers, tyrosine hydrozylase fusion protein as new carrier and its prepn |
| 01/01/2003 | CN1388126A 吡咯并三嗪和嘧啶化合物 Pyrrolo-triazine and pyrimidine compounds |
| 01/01/2003 | CN1387883A Chinese medicine extract and its application |
| 01/01/2003 | CN1387868A Prepn process and new use of general asiaticoside |
| 01/01/2003 | CN1387849A Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 01/01/2003 | CN1387848A Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 01/01/2003 | CN1097579C Ortho-substituted benzoylguanidines, process for their preparation, use and medicine containing them |
| 12/31/2002 | WO2002002117A1 Therapeutic or preventive medicines for mood disorders or anxiety disorders |
| 12/31/2002 | US6500987 Sertraline hydrochloride polymorphs |
| 12/31/2002 | US6500959 Pyrrolidine derivatives and processes for preparing same |
| 12/31/2002 | US6500868 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 12/31/2002 | US6500867 Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
| 12/31/2002 | US6500866 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 12/31/2002 | US6500863 Interleukin binding inhibitors such as n-(2-hydroxyl-3-amino sulfonyl-4-chlorophenyl)-n'-(2-bromophenyl)urea, used for prophylaxis of chemokine mediated diseases |
| 12/31/2002 | US6500862 Nonsettling mixtures of oleic, linoleic and palmitoleic acids, diethylene glycol, diethyl ether, n-methylpyrrolidone, polyethers, sodium laury sulfate, isopropanol, water and attractants having storage stability and chemical resistance |
| 12/31/2002 | US6500856 For therapy of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators |
| 12/31/2002 | US6500846 2-(4-chlorophenyl)-7-methoxychromen-4-one, as cyclin-dependent kinase inhibitors, used as anticarcinogenic agents or for prophylaxis of neurodegenerative disease |
| 12/31/2002 | US6500843 Inhibitors of rotamase enzyme activity |
| 12/31/2002 | US6500840 Central nervous system disorders |
| 12/31/2002 | US6500839 CRF receptor antagonists and methods relating thereto |
| 12/31/2002 | US6500837 Treating parkinson's disease |
| 12/31/2002 | US6500828 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 12/31/2002 | US6500825 Substituted 2-aminoacetamides and the use thereof |
| 12/31/2002 | US6500823 Energy deficiency of the cell caused by parp inhibition, in diabetes complications, in oxygen deficient status of the heart and brain, in neurodegenerative diseases, in the treatment of autoimmune and/or viral diseases |
| 12/31/2002 | US6500821 Treat various forms of epilepsies and of states of anxiety and tension. |
| 12/31/2002 | US6500819 Has an excellent anxiolytic effect |
| 12/31/2002 | US6500818 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 12/31/2002 | US6500809 Neural tissue edema is treated by circulating a hyperoncotic artificial cerebrospinal fluid in the cerebrospinal fluid pathway in the vicinity of edematous tissue to cause the edematous tissue to be dehydrated due to an oncotic gradient |
| 12/31/2002 | US6500641 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 12/31/2002 | US6500472 For enriching foods or beverages, anemia treatment |
| 12/31/2002 | US6500450 Composition for treating migraine headaches |
| 12/31/2002 | CA2414971A1 Drug for curing or preventing mood disorder or anxiety disorder |
| 12/31/2002 | CA2227814C Substituted benzylaminopiperidine compounds |
| 12/31/2002 | CA2201944C Analogs of keratinocyte growth factor having enhanced temperature stability |
| 12/31/2002 | CA2097732C Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus |
| 12/31/2002 | CA2064112C .alpha.-dihydroergocryptine pharmaceutical preparations with neuroprotective activity |
| 12/31/2002 | CA2029524C Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole |
| 12/27/2002 | WO2002103031A2 Methods for detecting and treating the early onset of aging-related conditions |
| 12/27/2002 | WO2002103018A1 Novel polypeptide and use thereof |
| 12/27/2002 | WO2002103016A2 Human tachykinin-related splice variants and compositions thereof |
| 12/27/2002 | WO2002102997A2 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| 12/27/2002 | WO2002102978A2 Human growth hormone antagonists |
| 12/27/2002 | WO2002102833A1 Novel endomorphine derivatives |
| 12/27/2002 | WO2002102832A1 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis |
| 12/27/2002 | WO2002102822A1 Adenosine derivative in polymorph ii form |
| 12/27/2002 | WO2002102821A1 Adenosine derivative in polymorph i form |
| 12/27/2002 | WO2002102808A2 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR |
| 12/27/2002 | WO2002102807A1 Novel isoxazolopyridone derivatives and use thereof |
| 12/27/2002 | WO2002102801A1 Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 12/27/2002 | WO2002102800A1 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 12/27/2002 | WO2002102797A1 1-methyl-4-(3-ethoxy-9h-thioxanthene-9-ylidene)-piperidine and its use as 5-ht2b and/or h1 antagonist |
| 12/27/2002 | WO2002102794A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 12/27/2002 | WO2002102782A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE |
| 12/27/2002 | WO2002102774A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 12/27/2002 | WO2002102771A1 Tryptase inhibitors |
| 12/27/2002 | WO2002102768A2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 12/27/2002 | WO2002102412A2 Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons |
| 12/27/2002 | WO2002102401A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 12/27/2002 | WO2002102397A1 Use of an extract of the root of balloon-flower for preventing and treating a degenerative brain disease or for enhancing memory |
| 12/27/2002 | WO2002102388A2 Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism |
| 12/27/2002 | WO2002102382A1 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS |
| 12/27/2002 | WO2002102381A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 12/27/2002 | WO2002102376A1 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT |
| 12/27/2002 | WO2002102375A2 Imidazole derivatives for modulating sodium channels |
| 12/27/2002 | WO2002102369A2 Agent for protection of retinal neurons |
| 12/27/2002 | WO2002102357A1 A coated nicotine-containing chewing gum, manufacture and use thereof |